FDA批准Celgene公司Abraxane用于胰腺癌治疗

2013-09-09 tomato 生物谷

2013年9月7日讯 /生物谷BIOON/ --美国生物制药公司赛尔基因(Celgene)9月6日宣布,Abraxane(紫杉醇蛋白质结合颗粒注射悬液)(白蛋白结合)补充新药申请(sNDA)获FDA批准,联合吉西他滨(gemcitabine)用于转移性胰腺癌患者的一线治疗。 迄今为止,吉西他滨作为胰腺癌的标准护理,已有超过15年的时间。而Abraxane+吉西他滨联合疗法,在临床试验中,

2013年9月7日讯 /生物谷BIOON/ --美国生物制药公司赛尔基因(Celgene)9月6日宣布,Abraxane(紫杉醇蛋白质结合颗粒注射悬液)(白蛋白结合)补充新药申请(sNDA)获FDA批准,联合吉西他滨(gemcitabine)用于转移性胰腺癌患者的一线治疗。

迄今为止,吉西他滨作为胰腺癌的标准护理,已有超过15年的时间。而Abraxane+吉西他滨联合疗法,在临床试验中,已被证明对关键疗效终点表现出临床意义的显着改善,包括总生存期,同时具有良好的安全性,该联合疗法将为胰腺癌患者提供一个重要的新治疗选择,并为今后的临床研究奠定基础。

Abraxane+吉西他滨联合疗法,是近8年来获批用于转移性胰腺癌的首个新疗法。该疗法的获批,是基于III期MPACT研究的数据。MPACT是一项开放标签、随机、国际性III期研究,研究中861例初治转移性胰腺癌患者随机接受ABRAXANE+吉西他滨联合疗法或吉西他滨单药疗法,研究数据表明,与吉西他滨单药疗法相比,ABRAXANE+吉西他滨联合疗法在总生存期(OS)、疾病无进展生存期(PFS)、整体响应率(ORR)上均表现出统计学意义的显着改善:OS(8.5个月 vs 6.7个月,HR=0.72,p<0.0001),死亡风险降低28%;PFS(5.5个月 vs 3.7个月,HR=0.69,p<0.0001),疾病进展或死亡风险降低31%;ORR(23% vs 7%,p<0.0001)。

在过去的20年中,在晚期胰腺癌患者中开展了超过30项随机III期临床试验,MPACT研究便是表现出总生存期利益的4项研究之一。

此前,2013年5月,FDA授予Abraxane优先审查资格,PDUFA日期为2013年9月21日。2013年4月,欧洲药品管理局(EMA)也接受审查Abraxane的营销授权申请(MAA),联合吉西他滨用于转移性胰腺癌患者的一线治疗。(生物谷Bioon.com)

关于胰腺癌:

胰腺癌是全球第8大癌症死因,在美国是第4大癌症死因。胰腺主要由2种细胞类型组成:外分泌和内分泌。外分泌肿瘤是目前最常见的一种胰腺癌,恶性腺瘤占胰腺癌症的95%。对于各个阶段的胰腺癌患者,5年的总体生存率约为6%,在美国这低于所有其他癌症的5年总体生存率。在欧洲,报告的5年生存率低于10%。

关于Abraxane:

Abraxane是紫杉醇的白蛋白结合形式,采用nab专利技术生产。Abraxane的配方中含有白蛋白,白蛋白是一种人源性蛋白质,Abraxane的配方中不含溶剂。

Abraxane于2005年1月在美国首先获准用于治疗联合化疗无效的转移性乳腺癌或辅助化疗6个月内复发的乳腺癌 。既往治疗必须包含一种蒽环类,除非有临床禁忌症。Abraxane还在下列地区获准用于治疗转移性乳腺癌:加拿大、印度、欧盟/欧洲经济区(EU/EEA)、韩国、中国、澳大利亚、不丹、阿联酋、尼泊尔、新西兰、日本、俄罗斯、斯里兰卡和阿根廷。

2012年10月,美国FDA批准Abraxane联合卡铂用于不适合治愈性手术或放疗的局部晚期或转移性非小细胞肺癌的一线治疗。此外,Abraxane也获日本和阿根廷获准用于非小细胞肺癌的治疗,并且还在日本获准用于胃癌的治疗。

Abraxane目前处于不同的研究阶段,用于下列癌症的潜在治疗:黑色素瘤、膀胱癌、卵巢癌以及乳腺癌、肺癌的扩展应用。(生物谷Bioon.com)

英文原文阅读

FDA okays Celgene's Abraxane for pancreatic cancer

U.S. Food and Drug Administration Approves ABRAXANE? in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer

-Approval Based on MPACT Study of ABRAXANE in Combination with Gemcitabine Demonstrating a Clinically Meaningful Increase in Overall Survival-

-First New Treatment Approved for Metastatic Adenocarcinoma of the Pancreas in Nearly 8 Years-

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) of ABRAXANE? (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) as first–line treatment for patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. Adenocarcinoma, a sub-type of exocrine tumors, accounts for about 95% of cancers of the pancreas.

“For more than 15 years, treatment with gemcitabine has been the standard of care in this disease. The addition of ABRAXANE to gemcitabine demonstrated meaningful improvements across key efficacy outcomes, including overall survival, with a well-characterized safety profile,” said Jean-Pierre Bizzari, M.D., Executive Vice President of Hematology and Oncology for Celgene Corporation.

“We are pleased that patients with advanced pancreatic cancer now have a new treatment option helping to expand the treatment landscape for the fourth leading cause of cancer death in the United States,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “The FDA approval of ABRAXANE is an important step for a disease that desperately needs treatment advances to improve patient outcomes. The Pancreatic Cancer Action Network will continue to work with the medical community to build upon this success and advance our goals in the fight against pancreatic cancer.”

ABRAXANE in combination with gemcitabine is the first new treatment approved for metastatic adenocarcinoma of the pancreas in nearly eight years. The approval was based on results from MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), an open-label, phase III, randomized, international study, that were featured at this year’s ASCO annual meeting and have been submitted for publication in a peer-reviewed journal. Over the past two decades, more than 30 randomized, phase III studies have been conducted in patients with advanced pancreatic cancer and the MPACT study was one of four studies to show an overall survival benefit. In the MPACT study, which involved 861 chemotherapy-na?ve patients with metastatic pancreatic cancer, ABRAXANE plus gemcitabine demonstrated a statistically significant improvement in median overall survival compared to gemcitabine alone (8.5 vs. 6.7 months) (HR 0.72, P<0.0001); a 28% overall reduction in risk of death. ABRAXANE plus gemcitabine demonstrated a median progression-free survival (PFS) of 5.5 vs. 3.7 months for gemcitabine alone (HR 0.69, P<0.0001); a 31% reduction in the risk of progression or death. The Overall Response Rate (ORR) was 23% for the ABRAXANE plus gemcitabine arm versus 7% in the gemcitabine alone arm (p<0.0001).

“Historically, patients with pancreatic cancer have not experienced benefit with many of the drugs so useful in other malignancies. This is beginning to change,” said Margaret A. Tempero, M.D., Director and Professor of Medicine, UCSF Pancreas Center. “The combination of ABRAXANE and gemcitabine represents an important new therapeutic option for patients with pancreatic cancer. It also provides a foundation for future clinical research.”

The most common adverse reactions (≥ 20%) with a ≥ 5% higher incidence in the ABRAXANE/gemcitabine treatment group are neutropenia, fatigue, peripheral neuropathy, nausea, alopecia, peripheral edema, diarrhea, pyrexia, vomiting, decreased appetite, rash, and dehydration. For additional safety information, please see Boxed Warning and Contraindications in the Important Safety Information.

The FDA had granted ABRAXANE a Priority Review designation in May 2013 with a PDUFA date of September 21, 2013. In April 2013, the European Medicines Agency (EMA) also accepted for review a Type II Variation to the current Marketing Authorization Application (MAA) for ABRAXANE, in combination with gemcitabine, for the first–line treatment of patients with metastatic adenocarcinoma of the pancreas. Celgene has submitted dossiers for registration in other countries/regions.

About the MPACT Study

In the MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study, a Celgene-sponsored, open-label, randomized, international study, a total of 861 patients were randomized 1:1 (431 patients to the ABRAXANE/gemcitabine group and 430 patients to the gemcitabine group). Patients randomized to ABRAXANE/gemcitabine received ABRAXANE as an intravenous infusion over 30-40 minutes at a dose of 125 mg/m2 followed by gemcitabine as an intravenous infusion over 30-40 minutes at a dose of 1000 mg/m2 given on Days 1, 8 and 15 of each 28-day cycle. In the comparator treatment group, gemcitabine monotherapy was administered at a dose of 1000 mg/m2 given weekly for 7 weeks followed by a 1-week rest period in Cycle 1 and in Cycle 2 and onwards was administered on Days 1, 8 and 15 of a 28 day cycle. The primary endpoint for the study was overall survival. Secondary endpoints were progression-free survival and overall response rate determined by independent radiological review. Other endpoints included progression-free survival and overall response rate as determined by the investigator, and the safety and tolerability of the combination in this patient population.

About Pancreatic Cancer

Pancreatic cancer is the fourth-leading cause of cancer-related death in the U.S. The pancreas is composed of two main cell types: exocrine and endocrine. Exocrine tumors are by far the most common type of pancreatic cancer. Adenocarcinoma is a sub-type of exocrine tumors and accounts for about 95% of cancers of the pancreas. For all stages of pancreatic cancer combined, the five-year survival rate is about 6%, which is the lowest of any cancer in the U.S. For metastatic pancreatic cancer, the five-year survival is approximately 2%.

About ABRAXANE?

ABRAXANE is an albumin-bound form of paclitaxel that is manufactured using patented nab? technology. ABRAXANE is formulated with albumin, a human protein, and is free of solvents.

In the United States, ABRAXANE was first approved in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ABRAXANE has been globally approved in more than forty countries for the treatment of metastatic breast cancer (MBC).

In October 2012, ABRAXANE was approved by the FDA for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ABRAXANE is also approved for the treatment of NSCLC in Argentina, Australia, Japan, and New Zealand. In addition, ABRAXANE is approved for gastric cancer in Japan.

In September 2013, the FDA approved ABRAXANE as first–line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

U.S. Regulatory Information for ABRAXANE

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy

ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2007440, encodeId=20fe200e44082, content=<a href='/topic/show?id=c4c01e7346' target=_blank style='color:#2F92EE;'>#Abraxane#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1773, encryptionId=c4c01e7346, topicName=Abraxane)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Feb 11 20:43:00 CST 2014, time=2014-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048530, encodeId=91c120485302f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Feb 18 08:43:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958919, encodeId=600d1958919db, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 20 20:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669190, encodeId=e19b1669190b0, content=<a href='/topic/show?id=054f445647' target=_blank style='color:#2F92EE;'>#Celgene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4456, encryptionId=054f445647, topicName=Celgene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c9326519105, createdName=zjubiostat, createdTime=Sun Aug 10 10:43:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839249, encodeId=3e7018392493c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Aug 22 03:43:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539194, encodeId=2429153919434, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Wed Sep 11 06:43:00 CST 2013, time=2013-09-11, status=1, ipAttribution=)]
    2014-02-11 wgsun
  2. [GetPortalCommentsPageByObjectIdResponse(id=2007440, encodeId=20fe200e44082, content=<a href='/topic/show?id=c4c01e7346' target=_blank style='color:#2F92EE;'>#Abraxane#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1773, encryptionId=c4c01e7346, topicName=Abraxane)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Feb 11 20:43:00 CST 2014, time=2014-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048530, encodeId=91c120485302f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Feb 18 08:43:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958919, encodeId=600d1958919db, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 20 20:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669190, encodeId=e19b1669190b0, content=<a href='/topic/show?id=054f445647' target=_blank style='color:#2F92EE;'>#Celgene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4456, encryptionId=054f445647, topicName=Celgene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c9326519105, createdName=zjubiostat, createdTime=Sun Aug 10 10:43:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839249, encodeId=3e7018392493c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Aug 22 03:43:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539194, encodeId=2429153919434, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Wed Sep 11 06:43:00 CST 2013, time=2013-09-11, status=1, ipAttribution=)]
    2014-02-18 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=2007440, encodeId=20fe200e44082, content=<a href='/topic/show?id=c4c01e7346' target=_blank style='color:#2F92EE;'>#Abraxane#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1773, encryptionId=c4c01e7346, topicName=Abraxane)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Feb 11 20:43:00 CST 2014, time=2014-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048530, encodeId=91c120485302f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Feb 18 08:43:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958919, encodeId=600d1958919db, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 20 20:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669190, encodeId=e19b1669190b0, content=<a href='/topic/show?id=054f445647' target=_blank style='color:#2F92EE;'>#Celgene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4456, encryptionId=054f445647, topicName=Celgene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c9326519105, createdName=zjubiostat, createdTime=Sun Aug 10 10:43:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839249, encodeId=3e7018392493c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Aug 22 03:43:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539194, encodeId=2429153919434, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Wed Sep 11 06:43:00 CST 2013, time=2013-09-11, status=1, ipAttribution=)]
    2014-08-20 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=2007440, encodeId=20fe200e44082, content=<a href='/topic/show?id=c4c01e7346' target=_blank style='color:#2F92EE;'>#Abraxane#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1773, encryptionId=c4c01e7346, topicName=Abraxane)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Feb 11 20:43:00 CST 2014, time=2014-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048530, encodeId=91c120485302f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Feb 18 08:43:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958919, encodeId=600d1958919db, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 20 20:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669190, encodeId=e19b1669190b0, content=<a href='/topic/show?id=054f445647' target=_blank style='color:#2F92EE;'>#Celgene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4456, encryptionId=054f445647, topicName=Celgene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c9326519105, createdName=zjubiostat, createdTime=Sun Aug 10 10:43:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839249, encodeId=3e7018392493c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Aug 22 03:43:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539194, encodeId=2429153919434, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Wed Sep 11 06:43:00 CST 2013, time=2013-09-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2007440, encodeId=20fe200e44082, content=<a href='/topic/show?id=c4c01e7346' target=_blank style='color:#2F92EE;'>#Abraxane#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1773, encryptionId=c4c01e7346, topicName=Abraxane)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Feb 11 20:43:00 CST 2014, time=2014-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048530, encodeId=91c120485302f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Feb 18 08:43:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958919, encodeId=600d1958919db, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 20 20:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669190, encodeId=e19b1669190b0, content=<a href='/topic/show?id=054f445647' target=_blank style='color:#2F92EE;'>#Celgene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4456, encryptionId=054f445647, topicName=Celgene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c9326519105, createdName=zjubiostat, createdTime=Sun Aug 10 10:43:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839249, encodeId=3e7018392493c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Aug 22 03:43:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539194, encodeId=2429153919434, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Wed Sep 11 06:43:00 CST 2013, time=2013-09-11, status=1, ipAttribution=)]
    2014-08-22 bugit
  6. [GetPortalCommentsPageByObjectIdResponse(id=2007440, encodeId=20fe200e44082, content=<a href='/topic/show?id=c4c01e7346' target=_blank style='color:#2F92EE;'>#Abraxane#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1773, encryptionId=c4c01e7346, topicName=Abraxane)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Feb 11 20:43:00 CST 2014, time=2014-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048530, encodeId=91c120485302f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Feb 18 08:43:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958919, encodeId=600d1958919db, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 20 20:43:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669190, encodeId=e19b1669190b0, content=<a href='/topic/show?id=054f445647' target=_blank style='color:#2F92EE;'>#Celgene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4456, encryptionId=054f445647, topicName=Celgene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c9326519105, createdName=zjubiostat, createdTime=Sun Aug 10 10:43:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839249, encodeId=3e7018392493c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Aug 22 03:43:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539194, encodeId=2429153919434, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Wed Sep 11 06:43:00 CST 2013, time=2013-09-11, status=1, ipAttribution=)]
    2013-09-11 HNYYM

相关资讯

Annals Oncol:吉西他滨联合索拉非尼治疗不改善晚期胰腺癌患者PFS

     《肿瘤学年鉴》(Annals of Oncology)近期发表的一项研究表明,吉西他滨基础上添加较不添加索拉非尼不改善晚期胰腺癌患者无进展生存(PFS)。   该研究纳入了局部晚期或转移性胰腺癌患者。患者既往未接受针对晚期肿瘤的治疗,体能状态评分为0~2分。   主要终点是PFS。   研究中,患者接受吉西他滨+索拉非尼或安慰剂治疗。   结果显示,从200

JCO:紫杉醇/吉西他滨维持化疗可改善转移性乳腺癌患者生存

在2013年4月8日在线出版的《临床肿瘤学杂志》(Journal of Clinical Oncology)上,韩国成均馆大学Young-Hyuck Im博士等人发表了KCSG-BR07-02临床III期试验(NCT00561119)结果,该研究主要面向接受六个周期紫杉醇/吉西他滨(PG)一线治疗后,取得病情控制的转移性乳腺癌(MBC)患者,旨在评价PG维持化疗方案是否在无进展生存时间(PFS)改

刘云鹏教授:晚期胰腺癌的治疗方案探索

作者:中国医科大学附属第一医院肿瘤内科  刘云鹏教授        胰腺癌是常见的高度恶性肿瘤之一,由于早期缺乏特异性临床表现,发现时多为晚期,在中国胰腺癌的手术治疗比例远高于欧美, 但总生存(OS)并没有得到提高,进一步证实了非R0 切除的所谓减瘤术并不能给晚期胰腺癌带来获益,应采用内科治疗为主的综合治疗。

辉瑞中止旗下淋巴瘤药物Inotuzumab的后期临床研究

辉瑞虽然最近有三款癌症药物连续获得批准,但它也遇到了挫折,公司于5月20日声称正在停止一款用于治疗侵袭性非霍奇金淋巴瘤药物的一项后期临床试验,因为独立监督员发现这款药物可能无法改善患者的生存期。辉瑞表示将继续在其它血液癌症方面对这款名为Inotuzumab ozogamicin的试验药物进行研究。 辉瑞肿瘤学业务单元负责临床开发和医疗事务的高级副总裁Mace Rothenberg在一项声明中说:

Br J Cancer:VG与VC治晚期非小细胞肺癌效果相似

     《英国癌症杂志》(Br J Cancer)近期发表的一项研究表明,晚期非小细胞肺癌(NSCLC)接受长春瑞滨+吉西他滨(VG)与长春瑞滨+卡铂(VC)方案治疗的总生存(OS)状况相似,但VG方案毒性状况稍优于VC方案。   该研究受试者为体能状态(PS)评分为0~2分的ⅢB/Ⅳ期NSCLC患者。   患者分别接受VG和VC方案治疗。   研究终点为OS、健康相关生活质量(HRQo

J Clin Oncol:一线吉西他滨/顺铂添加较不添加索拉非尼不延长晚期非鳞NSCLC OS

  《临床肿瘤学杂志》(J Clin Oncol)近期发表的一项研究表明,在晚期非鳞非小细胞肺癌(NSCLC)患者中,一线吉西他滨/顺铂添加较不添加索拉非尼治疗不延长其总生存期(OS)。   该研究在既往未接受化疗的不可切除ⅢB~Ⅳ期非鳞NSCLC患者中评估了索拉非尼+吉西他滨/顺铂的治疗效果和安全性。   该研究从2007年2月至2009年3月共纳入了904例NSCLC患